Indian pharma sector set for 8-10% growth this fiscal: CRISIL Ratings

Q: How long will it take to read this news story?

The story "Indian pharma sector set for 8-10% growth this fiscal: CRISIL Ratings" has 487 words across 18 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Indian pharma sector set for 8-10% growth this fiscal: CRISIL Ratings" was covered 7 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 287 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22577139</li><li>URL: https://beamstart.com/news/indian-pharma-sector-set-for-17266587228598</li></ul>

Business Standard Logo Business Standard 7h ago

Indian pharma sector set for 8-10% growth this fiscal: CRISIL Ratings - Business Standard

Quick Summary:

Domestic formulations revenue is driven by both chronic and acute therapeutic segments, while exports primarily come from formulations (80 per cent) and bulk drugs (20 per cent).

Looking ahead, CRISIL warns that large-scale, debt-funded acquisitions, regulatory challenges, potential price caps on raw materials, and litigation costs from US antitrust suits remain key monitorables for the sector.

The chronic segment, supported by rising lifestyle-related diseases and heightened health awareness post-pandemic, is expected to be a key contributor to domestic revenue growth.